Osteoporotic vertebral compression fracture (OVCF) patients had a proportion of secondary
fractures after percutaneous vertebroplasty (PVP). Denosumab and zoledronate acid is both
effective to prevent bone loss for OVCF postmenopausal women. However, trial evidence
comparing effect of denosumab vs zoledronate after PVP was unknown. The study aims to assess
the efficiency of denosumab vs zoledronate for OVCF patients bone mineral density (BMD), bone
turnover markers (BTMs), secondary fracture and adverse events after PVP.